The Norwegian Arthroplasty Register, Department of Orthopaedic Surgery, Haukeland University Hospital, Bergen, Norway.
Department of Clinical Medicine, University of Bergen, Bergen, Norway.
BMC Musculoskelet Disord. 2020 Sep 8;21(1):599. doi: 10.1186/s12891-020-03605-7.
Concerns have been raised that implants used in total hip replacements (THR) could lead to increased cancer risk. Several different materials, metals and fixation techniques are used in joint prostheses and different types of articulation can cause an increased invasion of particles or ions into the human body.
Patients with THR registered in the Norwegian Arthroplasty Register during 1987-2009 were linked to the Cancer registry of Norway. Patients with THR due to osteoarthritis, under the age of 75 at time of surgery, were included. Standardized incidence ratios (SIR) were applied to compare cancer risk for THR patients to the general population. Types of THR were divided into cemented (both components), uncemented (both components), and hybrid (cemented femoral and uncemented acetabular components). To account for selection mechanisms, time dependent covariates were applied in Cox-regression, adjusting for cancer risk the first 10 years after surgery. The analyses were adjusted for age, gender and if the patient had additional THR-surgery in the same or the opposite hip. The study follows the STROBE guidelines.
Comparing patients with THR to the general population in Norway we found no differences in cancer risk. The overall SIR for the THR-patients after 10 years follow-up was 1.02 (95% CI: 0.97-1.07). For cemented THR, the SIR after 10 years follow-up was 0.99 (95% CI: 0.94-1.05), for uncemented, 1.16 (95% CI: 1.02-1.30), and for hybrid 1.12 (95% CI: 0.91-1.33). Adjusted Cox analyses showed that patients with uncemented THRs had an elevated risk for cancer (hazard ratio: HR = 1.24, 95% CI: 1.05-1.46, p = 0.009) when compared to patients with cemented THRs after 10 years follow-up. Stratified by gender the increased risk was only present for men. The risk for patients with hybrid THRs was not significantly increased (HR = 1.07, 95% CI: 0.85-1.35, p = 0.55) compared to patients with cemented THRs.
THR patients had no increased risk for cancer compared to the general population. We found, however, that receiving an uncemented THR was associated with a small increased risk for cancer compared to cemented THR in males, but that this may be prone to unmeasured confounding.
人们担心全髋关节置换术(THR)中使用的植入物会增加癌症风险。关节假体中使用了多种不同的材料、金属和固定技术,不同类型的关节活动会导致更多的颗粒或离子侵入人体。
1987 年至 2009 年间在挪威关节置换登记处登记的 THR 患者与挪威癌症登记处相关联。纳入手术时年龄在 75 岁以下、因骨关节炎接受 THR 的患者。应用标准化发病比(SIR)比较 THR 患者与普通人群的癌症风险。将 THR 类型分为骨水泥固定(均为组件)、非骨水泥固定(均为组件)和混合(骨水泥固定股骨和非骨水泥固定髋臼组件)。为了考虑选择机制,在 Cox 回归中应用了时间依赖性协变量,在手术后的前 10 年调整癌症风险。分析调整了年龄、性别以及患者在同一或对侧髋关节是否接受了额外的 THR 手术。该研究遵循 STROBE 指南。
与挪威普通人群相比,我们发现 THR 患者的癌症风险没有差异。在 10 年随访后,THR 患者的总体 SIR 为 1.02(95%CI:0.97-1.07)。在 10 年随访后,骨水泥固定 THR 的 SIR 为 0.99(95%CI:0.94-1.05),非骨水泥固定 THR 的 SIR 为 1.16(95%CI:1.02-1.30),混合 THR 的 SIR 为 1.12(95%CI:0.91-1.33)。调整后的 Cox 分析显示,与骨水泥固定 THR 患者相比,非骨水泥固定 THR 患者在 10 年随访后癌症风险升高(风险比:HR=1.24,95%CI:1.05-1.46,p=0.009)。按性别分层,这种风险增加仅见于男性。混合 THR 患者的风险无显著增加(HR=1.07,95%CI:0.85-1.35,p=0.55),与骨水泥固定 THR 患者相比。
与普通人群相比,THR 患者的癌症风险没有增加。然而,我们发现与骨水泥固定 THR 相比,男性接受非骨水泥固定 THR 与癌症风险略有增加相关,但这可能容易受到未测量的混杂因素的影响。